SCHEMBL10246951

SCHEMBL10246951

Cc1ccc2[nH]c(C(=O)NC3CCCc4cc(C(=O)NO)ccc43)cc2c1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.51
PYGL P06737 3/20 0.48
PYGM P11217 1/20 0.48
TAOK1 Q7L7X3 1/20 0.46
TAOK3 Q9H2K8 1/20 0.46
TAS1R3 Q7RTX0 3/20 0.45
TAS1R1 Q7RTX1 3/20 0.45
GHSR Q92847 6/20 0.44
TP53 P04637 1/20 0.43
POLB P06746 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
KCNH2 Q12809 4/20 0.42
TAS1R2 Q8TE23 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10247020 0.89 PYGL (0.58) PYGLPYGMTAS1R3TAS1R1TAS1R2
SCHEMBL10246997 0.82 LMNA (0.62) LMNATAS1R3TAS1R1MEN1KMT2A
SCHEMBL10247155 0.80 LMNA (0.77) LMNATAS1R3TAS1R1MEN1KMT2A
SCHEMBL10247022 0.78 LMNA (0.48) LMNATAS1R3TAS1R1POLBMEN1
SCHEMBL10247230 0.78 LMNA (0.48) LMNATAS1R3TAS1R1POLBMEN1
SCHEMBL10252064 0.77 TAS1R3 (0.49) LMNATAOK3TAS1R3TAS1R1POLB
SCHEMBL10246933 0.76 DHODH (0.53) LMNATAOK1TAOK3TAS1R3TAS1R1
SCHEMBL10246865 0.74 LMNA (0.54) LMNATAS1R3TAS1R1MEN1KMT2A
SCHEMBL1264307 0.74 NPC1 (0.59) MEN1KMT2AHDAC1
SCHEMBL10247153 0.74 LMNA (0.50) LMNATAOK3TAS1R3TAS1R1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
WO-2012012322-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-01-26 WO disclosed
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACUTICALS, INC. (US) 2012-01-19 US disclosed
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACUTICALS, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC2 LMNA 1529/4885PYGL 4074/4885PYGM 3192/4885
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, H1-3 LMNA 2546/4885PYGL 4119/4885PYGM 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.